PTC Therapeutics, Inc. Earnings Per Share (Diluted)
PTC Therapeutics, Inc. (PTCT) reported Earnings Per Share (Diluted) of $0.92 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-07-30
- PTC Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was $0.92.
- PTC Therapeutics, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.03, a 100.30% decline year-over-year.
- PTC Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$1.45.
- PTC Therapeutics, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was $0.20.
- PTC Therapeutics, Inc. earnings per share, diluted for fiscal 2025 was $7.78.
- PTC Therapeutics, Inc. earnings per share, diluted for fiscal 2024 was -$4.73.
- PTC Therapeutics, Inc. earnings per share, diluted for fiscal 2023 was -$8.37.
- PTC Therapeutics, Inc. earnings per share, diluted for fiscal 2022 was -$7.79.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.92 10-Q · filed 2026-07-30 | $0.90 10-Q · filed 2026-07-30 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$0.40 derived: net income ÷ weighted average shares · filed 2026-07-30 | ||
| 2026-03-31 | -$0.03 10-Q · filed 2026-05-07 | -$1.56 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.37 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.17 derived: net income ÷ weighted average shares · filed 2026-07-30 | ||
| 2025-12-31 | -$1.45 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$1.30 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$2.11 derived: net income ÷ weighted average shares · filed 2026-07-30 | $7.78 10-K · filed 2026-02-19 | ||
| 2025-09-30 | $0.20 10-Q · filed 2025-11-04 | -$0.58 derived: net income ÷ weighted average shares · filed 2026-07-30 | $9.45 10-Q · filed 2025-11-04 | $9.17 derived: net income ÷ weighted average shares · filed 2026-07-30 | ||
| 2025-06-30 | -$0.83 10-Q · filed 2026-07-30 | $9.29 10-Q · filed 2026-07-30 | $9.14 derived: net income ÷ weighted average shares · filed 2026-07-30 | $7.91 derived: net income ÷ weighted average shares · filed 2026-07-30 | ||
| 2025-03-31 | $10.04 10-Q · filed 2026-05-07 | $9.80 derived: net income ÷ weighted average shares · filed 2026-05-07 | $8.67 derived: net income ÷ weighted average shares · filed 2026-05-07 | $7.51 derived: net income ÷ weighted average shares · filed 2026-05-07 | ||
| 2024-12-31 | -$0.85 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$2.24 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$3.53 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$4.73 10-K · filed 2026-02-19 | ||
| 2024-09-30 | -$1.39 10-Q · filed 2025-11-04 | -$2.68 derived: net income ÷ weighted average shares · filed 2025-11-04 | -$3.88 10-Q · filed 2025-11-04 | -$5.93 derived: net income ÷ weighted average shares · filed 2026-02-19 | ||
| 2024-06-30 | -$1.29 10-Q · filed 2025-08-07 | -$2.49 10-Q · filed 2025-08-07 | -$4.55 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$6.31 derived: net income ÷ weighted average shares · filed 2026-02-19 | ||
| 2024-03-31 | -$1.20 10-Q · filed 2025-05-06 | -$3.25 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$5.02 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$7.67 derived: net income ÷ weighted average shares · filed 2026-02-19 | ||
| 2023-12-31 | -$2.06 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$3.83 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$6.48 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$8.37 10-K · filed 2026-02-19 | ||
| 2023-09-30 | -$1.76 10-Q · filed 2024-11-07 | -$4.42 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$6.31 10-Q · filed 2024-11-07 | -$8.66 derived: net income ÷ weighted average shares · filed 2025-02-27 | ||
| 2023-06-30 | -$2.66 10-Q · filed 2024-08-08 | -$4.55 10-Q · filed 2024-08-08 | -$6.90 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$8.44 derived: net income ÷ weighted average shares · filed 2025-02-27 | ||
| 2023-03-31 | -$1.88 10-Q · filed 2024-04-25 | -$4.23 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$5.77 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$7.89 derived: net income ÷ weighted average shares · filed 2025-02-27 | ||
| 2022-12-31 | -$2.35 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$3.88 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$6.01 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$7.79 10-K · filed 2025-02-27 | ||
| 2022-09-30 | -$1.53 10-Q · filed 2023-10-26 | -$3.66 derived: net income ÷ weighted average shares · filed 2023-10-26 | -$5.43 10-Q · filed 2023-10-26 | -$7.46 derived: net income ÷ weighted average shares · filed 2024-02-29 | ||
| 2022-06-30 | -$2.13 10-Q · filed 2023-08-03 | -$2.62 10-Q · filed 2022-08-04 | -$3.91 10-Q · filed 2023-08-03 | -$4.40 10-Q · filed 2022-08-04 | -$5.94 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$7.83 derived: net income ÷ weighted average shares · filed 2024-02-29 |
| 2022-03-31 | -$1.78 10-Q · filed 2023-04-27 | -$3.81 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$5.70 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$7.38 derived: net income ÷ weighted average shares · filed 2024-02-29 | ||
| 2021-12-31 | -$2.03 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$3.92 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$5.60 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$7.43 10-K · filed 2024-02-29 | ||
| 2021-09-30 | -$1.89 10-Q · filed 2022-10-27 | -$3.57 derived: net income ÷ weighted average shares · filed 2022-10-27 | -$5.41 10-Q · filed 2022-10-27 | |||
| 2021-06-30 | -$1.68 10-Q · filed 2022-08-04 | -$3.51 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | -$1.83 10-Q · filed 2022-05-03 | |||||
| 2020-12-31 | -$6.64 10-K · filed 2023-02-21 | |||||
| 2019-12-31 | -$4.27 10-K · filed 2022-02-22 | |||||
| 2014-12-31 | -$0.84 10-K · filed 2015-03-02 | -$2.97 10-K · filed 2015-03-02 | ||||
| 2014-09-30 | -$0.93 10-K · filed 2015-03-02 | |||||
| 2014-06-30 | -$0.86 10-K · filed 2015-03-02 | |||||
| 2014-03-31 | -$0.58 10-K · filed 2015-03-02 | |||||
| 2013-12-31 | -$0.75 10-K · filed 2015-03-02 | -$5.18 10-K · filed 2015-03-02 | ||||
| 2013-09-30 | -$0.19 10-K · filed 2015-03-02 | -$5.40 10-Q · filed 2013-11-14 | ||||
| 2013-06-30 | -$5.51 10-K · filed 2015-03-02 | -$33.26 10-Q · filed 2013-08-13 | ||||
| 2013-03-31 | -$6527.30 10-K · filed 2015-03-02 | |||||
| 2012-12-31 | -$1380.13 10-K · filed 2014-03-06 | $42.50 10-K · filed 2015-03-02 | ||||
| 2012-09-30 | -$1605.53 10-K · filed 2014-03-06 | $39.41 10-Q · filed 2013-11-14 | ||||
| 2012-06-30 | $48.29 10-K · filed 2014-03-06 | $47.14 10-Q · filed 2013-08-13 | ||||
| 2012-03-31 | -$5992.61 10-K · filed 2014-03-06 | |||||
| 2011-12-31 | $4.55 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |